GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cardiff Oncology Inc.
The shares of Cardiff Oncology, a biotech company, reflect the potential of its leading targeted cancer drug. The stock's price follows a classic biotech pattern, with the company's value driven by expectations of clinical trial results.
Share prices of companies in the market segment - General oncology therapy
Cardiff Oncology, Inc. is a biopharmaceutical company developing the targeted drug onasertib for the treatment of various cancers in which the PLK1 gene plays a key role. We classify the company as a "General Oncology Therapy" company because its drug has broad potential. The chart below reflects the dynamics of this entire innovative sector.
Broad Market Index - GURU.Markets
Cardiff Oncology develops targeted therapies targeting the PLK1 protein for the treatment of various cancers. Its innovative approach makes it a component of the GURU.Markets index. The chart below compares its performance, reflecting investor expectations, with the overall market picture.
Change in the price of a company, segment, and market as a whole per day
CRDF - Daily change in the company's share price Cardiff Oncology Inc.
For Cardiff Oncology, daily price changes are an indicator of the high volatility inherent in the sector. They demonstrate the stock's sensitivity to research results and overall investor risk appetite, serving as an important parameter for analytical models on the System.GURU.Markets platform.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Cardiff Oncology, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with CRDF's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Cardiff Oncology is a biotech company focused on developing new cancer treatments. Its journey is marked by a series of clinical trials, each of which can dramatically change its share price. This scientifically based volatility is an integral part of overall market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cardiff Oncology Inc.
For Cardiff Oncology, Inc., the year-over-year trend is a story about the development of its targeted drug for the treatment of cancer with the KRAS mutation. Its 12-month market cap is entirely dependent on clinical trial data. Positive results could make its drug a vital part of therapy for one of the most difficult-to-treat forms of cancer.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing targeted therapies for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cardiff Oncology is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cardiff Oncology Inc.
Cardiff Oncology is a biotech company developing targeted cancer therapies. Its monthly performance reflects progress in clinical trials of its lead drug. Positive data on its efficacy and safety, presented at conferences, are the main driver of its market valuation growth.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Cardiff Oncology is a biotech company developing a targeted drug that targets a specific protein that plays a key role in the development of many types of cancer, including colorectal cancer. The graph below shows the overall dynamics in the oncology sector, reflecting the ongoing search for new targets for more effective therapy.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where news about clinical trials trumps broader market trends. The chart below shows the pulse of the broader market. Does Cardiff Oncology move in sync with it, or are breakthroughs in its R&D pipeline creating a completely independent story for the stock?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cardiff Oncology Inc.
Cardiff Oncology's weekly performance reflects the search for new approaches to cancer treatment. This biotech company's stock price is responding to clinical trial data demonstrating whether its drug can make standard chemotherapy more effective.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Cardiff Oncology develops targeted therapies for cancer treatment. Like many biotech companies, its shares react strongly to the publication of research data. This chart is your tool for analysis: is Cardiff's weekly stock price driven by the progress of its lead drug or by overall sentiment in the oncology sector?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cardiff Oncology is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Cardiff Oncology is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
CRDF - Market capitalization of the company Cardiff Oncology Inc.
Cardiff Oncology's market capitalization chart tells the story of the development of a targeted cancer drug (onvansertib). Its volatile dynamics are a direct response to the results of clinical trials in various combinations and for different tumor types. Its trajectory reflects the market's assessment of the drug's potential to become a key part of oncologists' arsenal.
CRDF - Share of the company's market capitalization Cardiff Oncology Inc. within the market segment - General oncology therapy
Cardiff Oncology develops targeted cancer therapies, specifically PLK1 inhibitors. Its market capitalization reflects the potential of its lead candidate, onasertib, in combination with other treatments. The chart below shows how the market views its scientific strategy in the highly competitive oncology field.
Market capitalization of the market segment - General oncology therapy
Cardiff Oncology is a biotech company developing targeted therapies for certain types of cancer. The chart below shows the overall market capitalization of the oncology sector. Its dynamics serve as a backdrop against which Cardiff is attempting to prove the efficacy of its drug in clinical trials.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cardiff Oncology is a clinical-stage biotech company developing targeted therapies for certain types of cancer. Its market capitalization is the market valuation of its lead drug candidate. Its movements on the overall chart reflect news from clinical trials that could change everything.
Book value capitalization of the company, segment and market as a whole
CRDF - Book value capitalization of the company Cardiff Oncology Inc.
Cardiff Oncology's book value is its capital allocated for clinical trials of a targeted drug that could improve the effectiveness of other cancer treatments. This provides a tangible, scientific foundation for the development of new combination therapies. How has this oncology asset changed? The chart below shows its dynamics.
CRDF - Share of the company's book capitalization Cardiff Oncology Inc. within the market segment - General oncology therapy
Cardiff Oncology develops targeted cancer treatments, which requires R&D laboratories and equipment. The chart shows the share of these tangible assets in the pharmaceutical sector, reflecting the physical foundation on which its clinical trials are built.
Market segment balance sheet capitalization - General oncology therapy
Cardiff Oncology develops targeted cancer therapies. This is a science-intensive process where intellectual property is more important than manufacturing plants. The book value chart will show how "light" this biotech company's capital base is.
Book value of all companies included in the broad market index - GURU.Markets
Cardiff Oncology develops targeted therapies to fight cancer. Its book value is represented by its research laboratories, clinical trial capital, and patent portfolio. The chart shows the material foundation upon which the development of next-generation oncology drugs is built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cardiff Oncology Inc.
Cardiff Oncology's balance sheet is its capital. Its market price reflects investors' faith in its targeted drug. The chart shows how the company's "optimism coefficient" changes with each clinical trial announcement. This is a valuation not of its current assets, but of its potential future blockbuster.
Market to book capitalization ratio in a market segment - General oncology therapy
Cardiff Oncology develops targeted cancer treatments. Its approach targets specific genetic mutations. The chart shows how much investors believe in the accuracy of its scientific approach and the potential success of its lead drug in clinical trials.
Market to book capitalization ratio for the market as a whole
Cardiff Oncology is developing a drug that targets a specific protein that plays a key role in the development of certain cancers, particularly colon cancer. This chart shows the overall market valuation, but how do investors value a biotech company that uses targeted therapy to fight cancer?
Debts of the company, segment and market as a whole
CRDF - Company debts Cardiff Oncology Inc.
Cardiff Oncology, a clinical-stage biotech, is focused on developing its lead drug. This chart shows how it is funding targeted trials for specific cancer types. It's a financial strategy with high risk and potentially enormous reward.
Market segment debts - General oncology therapy
Cardiff Oncology develops targeted drugs to treat specific mutations in cancer cells. Personalized oncology is a promising but expensive field. This chart shows how the company funds its clinical trials targeting specific patient groups compared to other biotech companies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cardiff Oncology Inc.
Cardiff Oncology is a biotech company focused on new cancer treatments. This chart shows its reliance on debt capital. In oncology, where the cost of developing a single drug can exceed a billion dollars, debt is an essential tool. The chart's dynamics reflect research progress and lender confidence.
Market segment debt to market segment book capitalization - General oncology therapy
Cardiff Oncology develops targeted therapies for cancer, specifically PLK1 inhibitors. This chart shows the collective debt burden of the oncology pharmaceutical industry. It helps understand how the industry as a whole finances its expensive clinical trials and how Cardiff's financial model fits into this trend.
Debt to book value of all companies in the market
Cardiff Oncology develops targeted therapies for cancer treatment. Like many companies in this sector, it is in clinical trials, requiring significant investment with no guarantee of success. The overall market debt burden is secondary here, as the company's key risks and funding sources lie in the scientific and venture capital arenas.
P/E of the company, segment and market as a whole
P/E - Cardiff Oncology Inc.
This metric for Cardiff Oncology, a biopharmaceutical company, illustrates investor expectations. Its value is based not on current profits, but on the potential of its targeted drug for treating various types of cancer, especially in combination with other therapies. It is an assessment of future clinical success in the complex field of oncology.
P/E of the market segment - General oncology therapy
The targeted cancer therapy being developed by Cardiff Oncology is personalized medicine. This chart shows the average rating for biopharmaceutical companies. It helps to understand that Cardiff, with its mutation-targeted drug, is being evaluated based on its potential to become an important part of combination therapy.
P/E of the market as a whole
Cardiff Oncology, Inc. is developing a targeted drug for the treatment of various cancers, including colon cancer. The company focuses on a specific genetic mutation, an example of personalized medicine. This biotech sentiment chart helps understand how the market views Cardiff Oncology's chances of success in its niche and the potential for expansion into other indications.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cardiff Oncology Inc.
Cardiff Oncology develops targeted therapies for cancers with specific genetic mutations. This chart shows investor expectations for the clinical progress of its lead drug, onasertib. The dynamics reflect the market's confidence in the potential of this new approach to cancer treatment.
%20P%2FE%20Cardiff%20Oncology%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cardiff-Oncology-Inc.&v=1772513816719 "Chart of the company's future (projected) P/E Cardiff Oncology Inc.")
Future (projected) P/E of the market segment - General oncology therapy
Cardiff Oncology is a biotech company developing the targeted cancer drug onasertip. This chart shows average profitability expectations for the oncology sector. It provides insight into how investors view the drug's clinical data and its potential in various combinations for treating difficult-to-treat tumors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772513816763 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Cardiff Oncology, Inc. is a clinical-stage biotech company developing targeted therapies for cancer, specifically drugs targeting the PLK1 protein. This chart shows investor risk appetite. For a company with a highly specialized approach, it reflects the market's willingness to invest in new mechanisms for treating cancer.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513816803 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cardiff Oncology Inc.
Cardiff Oncology, Inc. is a clinical-stage biotechnology company whose lead drug targets a specific protein that plays a key role in the development of certain types of cancer. The financial results shown here represent investments in clinical research. The chart shows the cost of developing targeted therapy for cancer patients.
Profit of companies in the market segment - General oncology therapy
Cardiff Oncology is an oncology company developing the targeted drug Onasertip for the treatment of various cancers, particularly those associated with mutations in the PLK1 gene. The company is conducting clinical trials in several areas. This chart illustrates how precision medicine and targeted therapy are shaping the future of oncology and impacting profitability in the sector.
Overall market profit
Cardiff Oncology is a biotechnology company developing targeted therapies for cancer treatment. Its lead drug targets a specific protein that plays a role in tumor growth. The company's success depends on the results of clinical trials. This overall market return chart provides a backdrop against which investors make funding decisions for such innovative projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cardiff Oncology Inc.
Cardiff Oncology is a clinical-stage oncology company developing a targeted drug for the treatment of cancers with specific genetic mutations. The revenue forecast reflected here represents analysts' estimates of the likelihood of success of its lead drug in clinical trials and its potential market reach.
%20profit%20of%20the%20company%20Cardiff%20Oncology%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cardiff-Oncology-Inc.&v=1772513817081 "Graph of future (projected) profit of the company Cardiff Oncology Inc.")
Future (predicted) profit of companies in the market segment - General oncology therapy
Cardiff Oncology is an oncology company developing the targeted drug Onansertib, which targets the key protein PLK1 for the treatment of various cancers. This chart shows the revenue forecast for the general oncology therapeutics sector, allowing one to assess how Cardiff's specific development fits into the overall cancer treatment landscape and its prospects.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772513817150 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Cardiff Oncology is a biotechnology company developing targeted therapies for cancer treatment. Its prospects depend on the success of its clinical programs. This graph, reflecting investor risk appetite, influences the overall capital flow into the biotechnology sector, which funds Cardiff's research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513817254 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cardiff Oncology Inc.
Cardiff Oncology is developing a targeted cancer drug targeting the PLK1 protein. This chart shows how investors view the potential of its lead candidate. The revenue estimate is based on positive clinical trial results and the demand for its therapy in oncology.
P/S market segment - General oncology therapy
Cardiff Oncology is a biotech company developing the targeted drug onasertib for the treatment of various types of cancer. This chart shows the industry average market capitalization to revenue ratio. It reflects how investors view the company's clinical progress and the potential of its lead drug in combination with other treatments.
P/S of the market as a whole
Cardiff Oncology is a biotech company developing the targeted drug onvanertib for the treatment of cancers with specific genetic mutations. It's an example of personalized medicine. This overall market valuation chart helps understand how investors value companies focused on narrow but clearly defined segments within oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cardiff Oncology Inc.
Cardiff Oncology is a biotech company developing a targeted drug for cancer treatment. This chart shows its valuation relative to future projected sales. It reflects investor expectations for the success of its lead candidate in clinical trials for various tumor types.
%20P%2FS%20Cardiff%20Oncology%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cardiff-Oncology-Inc.&v=1772513817393 "The graph of the company's future (projected) P/S Cardiff Oncology Inc.")
Future (projected) P/S of the market segment - General oncology therapy
Cardiff Oncology is a biotech company developing a targeted drug (onvasertib) for the treatment of various cancers, particularly those with mutations in the RAS genes. This chart shows how investors view the potential of its lead candidate and future revenue compared to other clinical-stage oncology companies.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772513817453 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Cardiff Oncology is a clinical-stage biotechnology company developing targeted therapies for cancer treatment. Its success depends entirely on the results of clinical trials. This graph of general expectations for CRDF is a baseline. The company's value is determined by scientific data, not the overall economic climate. Positive results will create their own trend.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513817487 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cardiff Oncology Inc.
This chart shows the trajectory of a biopharmaceutical company. For Cardiff Oncology, which develops targeted cancer therapies, it reflects funding and, potentially, partnerships. Significant changes in the trajectory will depend on the success of clinical trials of their lead drug.
Sales of companies in the market segment - General oncology therapy
Cardiff Oncology develops targeted therapies for cancer treatment, specifically a PLK1 inhibitor. The company focuses on combinations with other drugs. This chart reflects revenue in the oncology field. The success of Cardiff's clinical programs could offer new effective treatment options for patients and significantly contribute to the growth of the entire sector.
Overall market sales
Cardiff Oncology is developing a targeted drug for the treatment of cancers with mutations in the KRAS gene, long considered untreatable. The company is at the forefront of oncology. Its successes exemplify how scientific progress opens new treatment options and creates new segments in the pharmaceutical market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cardiff Oncology Inc.
Cardiff Oncology is developing the targeted drug onasertib for the treatment of cancers with specific genetic mutations. The company's future sales are dependent on the results of clinical trials and potential approval for various tumor types.
%20sales%20of%20the%20company%20Cardiff%20Oncology%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cardiff-Oncology-Inc.&v=1772513817585 "Schedule of future (projected) sales of the company Cardiff Oncology Inc.")
Future (projected) sales of companies in the market segment - General oncology therapy
Cardiff Oncology, Inc. is developing a targeted drug for the treatment of various types of cancer. The forecast for the general oncology therapeutics sector demonstrates the size and diversity of this market. The chart helps understand how a new drug with a unique mechanism of action could find its niche among existing treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772513817700 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Cardiff Oncology is a biotechnology company developing targeted therapies for cancer treatment. Its valuation is determined by the potential of its lead drug and the results of clinical trials. This general economic activity graph does not impact operating performance but is important for assessing the overall investment climate, which influences the financing of biotechnology companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513817714 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cardiff Oncology Inc.
Cardiff Oncology is an oncology company developing targeted therapies. Its financial performance is focused on the clinical trial costs of its lead drug. This chart shows not current profit, but rather the capital burn rate, a key metric for biotech companies seeking to bring a new product to market.
Market segment marginality - General oncology therapy
Cardiff Oncology is a biotech company developing targeted therapies for various types of cancer. Its financial performance reflects its focus on clinical trials to validate the efficacy of its lead candidate. This chart provides insight into the company's operating model compared to other oncology companies.
Market marginality as a whole
Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing targeted therapies for cancer. This chart shows average revenue. In this context, Cardiff exemplifies how a small company can focus on a specific molecular target. Its future profitability depends entirely on the success of this single approach.
Employees in the company, segment and market as a whole
Number of employees in the company Cardiff Oncology Inc.
Cardiff Oncology develops targeted therapies for cancer treatment. Its small, focused team of scientists and clinicians is working to advance its lead drug, ovansertib. Growth on this chart will directly correlate with the expansion of the clinical trial program and the study of the drug's potential in various tumor types.
Share of the company's employees Cardiff Oncology Inc. within the market segment - General oncology therapy
Cardiff Oncology is a biotech company developing targeted therapies for various cancer types, including those with KRAS mutations. This chart illustrates its focus. It reflects the percentage of oncologists and clinical trialists working on this specific and important molecular target that Cardiff attracts.
Number of employees in the market segment - General oncology therapy
Cardiff Oncology is developing a targeted drug for the treatment of various cancers, including colon cancer. This chart shows the dynamics in the precision oncology segment. The growing number of clinicians and scientists involved is due to the drug's advancement through clinical trials, which are designed to prove its efficacy in specific patient groups.
Number of employees in the market as a whole
Cardiff Oncology, Inc. is a company focused on developing targeted therapies for cancer treatment. Their need for specialists is dictated solely by the stage of drug development. The overall economic situation, reflected in this chart, is secondary to them. Successful clinical data is what attracts investors and allows them to hire the best oncologists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cardiff Oncology Inc. (CRDF)
Cardiff Oncology is developing a targeted cancer therapy targeting a specific protein, PLK1. This is a precision medicine approach. This chart illustrates the company's intellectual property-based business model. The high market capitalization per employee indicates that the market highly values the potential of their unique drug in the fight against difficult-to-treat cancers.
%20of%20the%20company%20Cardiff%20Oncology%20Inc.%20(CRDF)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cardiff-Oncology-Inc.-CRDF&v=1772513817967 "Chart of market capitalization per employee (in thousands of dollars) of the company Cardiff Oncology Inc. (CRDF)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Cardiff Oncology develops targeted therapies for cancer treatment. The company's value is concentrated in its lead drug and scientific platform. This chart illustrates a typical biotech situation: a small but highly skilled team creates intellectual property valued in the hundreds of millions of dollars, hence the high valuation.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772513817969 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Cardiff Oncology is a clinical-stage company developing targeted therapies for cancer treatment. Its lead drug targets the PLK1 protein. This graph indicates a high employee valuation, as success in clinical trials could validate the new treatment approach and open a large market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513817973 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cardiff Oncology Inc. (CRDF)
Cardiff Oncology is a biotech company developing targeted therapies for cancer. Their lead candidate (Onvansertib) targets a specific protein involved in tumor growth. They are an R&D company. This indicator is negative. It shows how much the company invests in each employee (scientist, clinician) to advance their drug through clinical trials.
%20Chart%20Cardiff%20Oncology%20Inc.%20(CRDF)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cardiff-Oncology-Inc.-CRDF&v=1772513817989 "Company Profit Per Employee (in thousands of dollars) Chart Cardiff Oncology Inc. (CRDF)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Cardiff Oncology (CRDF) is a biotech company developing targeted therapies for cancer treatment. For a clinical-stage company, this schedule is a benchmark for the future. CRDF's profitability per employee will depend on whether their drug (for example, Onansertib) proves effective and receives approval, allowing them to monetize the team's years of R&D investment.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772513818019 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Cardiff Oncology (CRDF) is a biotech company targeting specific mutations in cancer. These companies are in the clinical stage, meaning they have no commercial revenue and high R&D costs. This chart reflects the investment in the team of scientists and physicians who are developing targeted drugs through multi-year clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513818021 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cardiff Oncology Inc. (CRDF)
Cardiff Oncology is a clinical-stage biotech company. This chart reflects its focus on research rather than sales. A lack of revenue is normal. This metric demonstrates potential: a successful drug can generate massive revenue, leading to explosive growth in revenue per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cardiff-Oncology-Inc.-CRDF&v=1772513818023 "Sales chart per company employee Cardiff Oncology Inc. (CRDF)")
Sales per employee in the market segment - General oncology therapy
Cardiff Oncology is a biotech company developing a targeted cancer therapy (a PLK1 inhibitor). During the R&D phase, this metric reflects how effectively their research team generates revenue (e.g., from partnerships) per employee. It is a key indicator for assessing progress in this competitive field.
Sales per employee for the market as a whole
Cardiff Oncology is a clinical-stage biotech company developing a targeted cancer therapy (a PLK1 inhibitor). It's an R&D company. This chart shows revenue per employee. Predictably, it's zero. It emphasizes that the company doesn't sell products but rather invests in lengthy and expensive clinical trials, where its scientific staff creates future value.
Short shares by company, segment and market as a whole
Shares shorted by company Cardiff Oncology Inc. (CRDF)
Cardiff Oncology is a biotech company developing targeted therapies for cancer. Its lead candidate targets a specific protein (PLK1). This chart shows bearish bets. Bearish bets are that the candidate will fail to prove effective in clinical trials or will exhibit unacceptable toxicity, which is a binary risk for the company.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cardiff-Oncology-Inc.-CRDF&v=1772513818072 "Short Shares Chart for the Company Cardiff Oncology Inc. (CRDF)")
Shares shorted by market segment - General oncology therapy
Cardiff Oncology is a biotech company developing targeted therapies for cancer, specifically targeting the PLK1 gene. This chart shows overall short positions in the biotech sector. A high chart reflects general market skepticism about the sector, possibly due to fears of research failures or tightening regulatory policies.
Shares shorted by the overall market
Cardiff Oncology (CRDF) is a clinical-stage biotech. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like CRDF in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cardiff Oncology Inc. (CRDF)
Cardiff Oncology is a clinical-stage biotech. The stock is extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold levels (<30) often reflect research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cardiff-Oncology-Inc.-CRDF&v=1772513818131 "RSI 14 indicator chart for the company's stock Cardiff Oncology Inc. (CRDF)")
RSI 14 Market Segment - General oncology therapy
Cardiff (CRDF) is an oncology "sniper." It's a biotech that "attacks" a *rare* target (PLK1) to treat cancer (including pancreatic cancer). The RSI_14_Seg for "General Oncology Therapy" (biotech) shows the overall sentiment. It helps us understand: is CRDF's volatility due to its R&D or is the *entire* sector overheated?
RSI 14 for the overall market
Cardiff Oncology (CRDF) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CRDF (Cardiff Oncology Inc.)
Cardiff Oncology is a biotech company developing a drug (Onvansertib) for the treatment of cancer. Their approach involves inhibiting the PLK1 protein to make chemotherapy more effective. This chart shows the analysts' average 12-month forecast, representing their collective bet on the success of this combination therapy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CRDF-Cardiff-Oncology-Inc.&v=1772513818191 "A chart showing analyst consensus forecasts for the expected stock price. CRDF (Cardiff Oncology Inc.)")
The difference between the consensus estimate and the actual stock price CRDF (Cardiff Oncology Inc.)
Cardiff Oncology (CRDF) is an oncology company developing a targeted therapy (a PLK1 inhibitor) for cancer treatment. This chart is a classic biotech barometer. It measures the vast gap between the current speculative price and the analyst consensus price target. This gap reflects the enormous potential experts believe for the success of their R&D.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CRDF-Cardiff-Oncology-Inc.&v=1772513818198 "A chart showing the difference between the consensus forecast and the actual stock price. CRDF (Cardiff Oncology Inc.)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Cardiff Oncology is a biotech company developing a drug (Onvansertib) for the treatment of the most challenging cancers with the KRAS mutation (pancreatic and colon cancer). This chart shows analysts' overall expectations across the oncology sector. It reflects whether experts believe targeted therapy will be successful.
Analysts' consensus forecast for the overall market share price
Cardiff Oncology is a biotech company developing a targeted cancer drug (Onansertib) that inhibits (blocks) a key protein involved in tumor growth. This chart shows the overall risk appetite. For Cardiff, a high-risk clinical-stage company, overall market optimism is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cardiff Oncology Inc.
Cardiff Oncology is a clinical-stage biotech company focused on developing targeted therapies for cancer. Their flagship drug targets a specific protein (PLK1), which is a key driver of tumor growth in many tumors. This chart is a pure indicator of faith in their science. It doesn't reflect revenue, but rather a speculative estimate of their R&D progress and clinical trial data.
AKIMA Market Segment Index - General oncology therapy
Cardiff Oncology is a clinical-stage company whose lead drug (Onansertib) targets a specific protein (PLK1) to make chemotherapy more effective in treating cancer. This chart shows the average oncology sector index, allowing investors to assess how Cardiff's approach to combination therapy compares to the industry average.
The AKIM Index for the overall market
Cardiff Oncology is a biotech company developing the drug onvansertib for the treatment of various types of cancer (in combination with other drugs). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is striving to prove the effectiveness of its approach, compares to overall economic trends.
